A French biotech company has published positive results for a treatment against lung cancer. A crucial step before being able to consider marketing this vaccine.
The information caused a stir in the world of research: a therapeutic vaccine has proven its effectiveness – partial but quantifiable – in the fight against lung cancer. This treatment is called Tedopi. It was designed by the biotech company Ose Immunotherapeutics based in Nantes (Loire-Atlantique).
More than a year after the start of a clinical trial on 219 patients, “44.1% of these patients were still alive” states the study published in the scientific journal “Annals of Oncology” on September 11, 2023. This phase constitutes the third step of the process before being able to consider marketing the product.
We are pleased to announce that positive data from the Phase 3 clinical trial evaluating TEDOPI, our therapeutic vaccine for non-small cell lung cancer, has been published in the journal Annals of Oncology. https://t.co/GeoFLu4N6h pic.twitter.com/ujdjcBaYht
— OSE Immunotherapeutics – Biotechs & immunotherapy (@OSEImmuno) September 11, 2023
Tedopi is a therapeutic treatment aimed at patients who have relapsed after undergoing chemotherapy and immunotherapies. “Administered as a monotherapy, it reduces the risk of death by more than 40% compared to chemotherapy, while maintaining a better quality of life for these patients”, affirmed the Nantes company which wishes to offer its product as an alternative to the multiplication of chemotherapies. which cause serious side effects.
A new phase of clinical trial before considering the marketing of the vaccine
Nicolas Poirier, the general director of Ose Immunotherapeutics, explained that “Tedopi targets 7,000 to 10,000 patients per year in France out of 48,000 cases of lung cancer and 100,000 patients per year in total in Europe, the United States and in China.” The vaccine aims to treat “non-small cell cancer”, the most common form in people affected by lung cancer.
But because of the Covid health crisis, the threshold of 300 patients to participate in this clinical trial was not crossed. The company indicated to Echoes that “health authorities in Europe and the United States are requesting a new phase 3 trial on more than 300 people. It will be launched in early 2024, with the aim of a marketing application in 2027”.